Profilo
Marina Udier currently works at Nouscom AG, as Chief Executive Officer & Director from 2020, Nouscom Srl, as Chief Executive Officer & Director, and Celyad Oncology SA, as Independent Director from 2011.
Dr. Udier also formerly worked at Novartis AG, as Head-Global Commercial and Versant Venture Management LLC, as Chief Operating Officer.
Dr. Udier received her doctorate degree from Yale University.
Posizioni attive di Marina Udier
| Società | Posizione | Inizio |
|---|---|---|
| CELYAD ONCOLOGY SA | Direttore/Membro del Consiglio | 11/01/2011 |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Amministratore Delegato | 01/05/2019 |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Amministratore Delegato | - |
Precedenti posizioni note di Marina Udier
| Società | Posizione | Fine |
|---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Direttore operativo | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formazione di Marina Udier
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Celyad Oncology SA
Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products | Health Technology |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Health Technology |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Commercial Services |
















